FRESH THINKING, BETTER OUTCOMES

Your products touch people's lives. Pharmatech Associates delivers pragmatic solutions that help pharmaceutical, biotech, medical device and diagnostic companies improve their product and process development, their quality systems and compliance, their commissioning and validation and their trouble-shooting and remediation, across  the entire product lifecycle, from inception to market and beyond. 

And that means better outcomes for our clients’ patients.

WHAT'S NEW?

Pharmatech Associates, Inc. is a 2015 Host Sponsor of ISPE’s North American Conferences More News  
Our process

VALUE IN OUR PROCESS

The Pharmatech Difference

Our Subject Matter Experts have fully integrated development knowledge, hands on experience, and the ability to respond rapidly with pragmatic solutions, by applying proven and effective systems and practices. Our diligence in managing budget and timeline processes provides measurable value. As a result, our clients consistently rank us in the top-tier of life sciences industry consultants providing similar services. For Pharmatech, this has translated into a customer retention rate among the best in the industry, with some clients choosing to partner with Pharmatech since its inception in 1995.

LEARN MORE ABOUT WHAT WE DO  

LEARN HOW THE PHARMATECH DIFFERENCE CAN WORK FOR YOU

1.510.732.0177

29

Active Clients

30

Active Client Sites

86

Separate Active Projects

12

Countries

FRESH THINKING, BETTER OUTCOMES

The Pharmatech Difference

Bikash Chatterjee, President and Chief Scientific Officer, introduces you to the breadth and depth of knowledge and expertise possessed by our staff of Associates and SMEs at Pharmatech, and explains our unique approach to advising and providing technical services to our clients, that has been the basis for our decades of success in the Regulated Life Science industry.

LEARN MORE ABOUT WHAT WE DO  

Contact Us

Pharmatech Associates, Inc.
22320 Foothill Blvd. Suite 330
Hayward CA 94541

Phone: 510.732.0177
Fax: 510.732.1992 
TF: 877.787.0177

  Let’s Connect!

Quality Circle: Profitability, Integrity and the Cost of Poor Quality

As major blockbuster drugs come off patent, the scramble among generics to capture these new markets is just beginning. We can expect the U.S. market to experience continued change and consolidation with cost cutting remaining at the top of the priority list for big pharma. We can also expect emerging market drug powerhouses to try and gain market share as these blockbusters come off patent.

12/ 16/ 2014

READ FULL BLOG POST